PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
31670229-11	2019	Compared with vehicle (phosphate-buffered saline), thalidomide significantly inhibited the secretion of IFN-gamma and IL-17 in ITP mouse and reduced the expression of CD68 in spleen.	Thalidomide	51-62	interleukin 17A	Mus musculus	118-123	
25905462-8	2015	RESULTS: The mice with thalidomide treatment showed significantly reduced levels of allergen-induced BALF and lung inflammation, AHR, and the expression of a number of pro-inflammatory cytokines and mediators including Th2 related, IL-17 cytokines, and altered levels of allergen-specific IgG1/IgG2a.	Thalidomide	23-34	interleukin 17A	Mus musculus	232-237	
31840939-6	2020	RESULTS: Thal treatment: (a) reduced skin, and pulmonary tissue fibrosis, inflammation score, and hydroxyproline content (P < .001) in BLM-induced SSc mice; (b) reduced the percentages of Th17 cells and associated interleukin (IL)-17A expression (both P < .05) but increased the percentages of Treg cells and its transcription factor Foxp3 expression (both P < .05); (c) correlation analysis found positive correlations between Th17/Treg ratio, the inflammatory score of the skin and pulmonary tissues, hydroxyproline content, and type I collagen messenger RNA expression (r = .8546, .8656, .6902, .6807, .8118, and .8424, respectively, P < .01); (d) Thal inhibited TGF-beta1 expression and Smad3 phosphorylation (both P < .05); (e) TGF-beta1 was positively correlated with the IL-17A and Th17/Treg ratio (r = .5856, P = .005; r = .6684, P = .0107, respectively).	Thalidomide	9-13	interleukin 17A	Mus musculus	793-799	
22901832-9	2012	Thalidomide treatment also significantly decreased plasma levels of nitric oxide and pancreatic proinflammatory cytokines [tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, IL-6, IL-12, IL-17 and interferon (IFN)-gamma)] while increased anti-inflammatory cytokine IL-10.	Thalidomide	0-11	interleukin 17A	Mus musculus	195-200	
31578565-8	2020	The mice treated with ITC/Thal and CMX/Thal showed intense weight loss, increased deposition of reticulin fibers, high pulmonary concentrations of CCL3, IFN-gamma and VEGF, and decreased concentrations of IL-6, IL-1beta, IL-17, and TGF-beta1.	Thalidomide	26-30	interleukin 17A	Mus musculus	221-226	
31578565-8	2020	The mice treated with ITC/Thal and CMX/Thal showed intense weight loss, increased deposition of reticulin fibers, high pulmonary concentrations of CCL3, IFN-gamma and VEGF, and decreased concentrations of IL-6, IL-1beta, IL-17, and TGF-beta1.	Thalidomide	39-43	interleukin 17A	Mus musculus	221-226	
31920668-4	2019	Herein, our study demonstrated that thalidomide protected colon mucosa against trinitro-benzene-sulfonic acid (TNBS)-induced injury, diminished inflammatory infiltration and levels of IFN-gamma, IGF-1, IL-6, IL-17, TNF-alpha, while increased the levels of IL-10 and TGF-gamma.	Thalidomide	36-47	interleukin 17A	Mus musculus	208-213